

John P H Wilding

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8540760/john-p-h-wilding-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

320
papers

25,197
citations

68
h-index

155
g-index

360
ext. papers

30,726
ext. citations

7.8
avg. IF

7.22
L-index

#	Paper	IF	Citations
320	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.. <i>Diabetes Care</i> , 2022 , 45, e27-e29	14.6	1
319	Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 61-71	6.7	
318	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.. <i>Diabetes Therapy</i> , 2022 , 13, 847	3.6	2
317	Adjunctive Therapy, Including Pharmacotherapy 2022 , 279-296		
316	Economic impacts of overweight and obesity: current and future estimates for eight countries. <i>BMJ Global Health</i> , 2021 , 6,	6.6	14
315	Exercise in Obesity-the Role of Technology in Health Services: Can This Approach Work?. <i>Current Obesity Reports</i> , 2021 , 1	8.4	0
314	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. <i>European Journal of Heart Failure</i> , 2021 , 23, 1026-1036	12.3	16
313	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. <i>Annals of Medicine</i> , 2021 , 53, 2072-2089	1.5	10
312	Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity?. <i>BMJ Open</i> , 2021 , 11, e044519	3	
311	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1159-1167	14.6	7
310	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021 , 384, 989	59.2	351
309	Short-Term Physical Inactivity Induces Endothelial Dysfunction. <i>Frontiers in Physiology</i> , 2021 , 12, 659834	4.6	0
308	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). <i>Journal of the Endocrine Society</i> , 2021 , 5, A10-A10	0.4	78
307	Realising the full potential of data-enabled trials in the UK: a call for action. <i>BMJ Open</i> , 2021 , 11, e043906		1
306	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. <i>Drugs</i> , 2021 , 81, 1243-1255	5.1	1
305	Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2303-2310	4	3
304	A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with xenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. <i>BMJ Open</i> , 2021 , 11, e045663	3	2

303	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1805-1815	14.6	10
302	The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. <i>Diabetologia</i> , 2021 , 64, 288-303	10.3	8
301	Cardiovascular outcome trials in obesity: A review. <i>Obesity Reviews</i> , 2021 , 22, e13112	10.6	12
300	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 29-38	6.7	11
299	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1020-1029	6.7	8
298	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021 , 64, 1226-1234	10.3	4
297	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 801-810	16.2	4
296	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. <i>Lancet, The</i> , 2021 , 398, 262-276	40	35
295	Metabolically healthy obesity: time for a change of heart?. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 519-522	14.2	0
294	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2573-2581	14.6	0
293	Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. <i>International Journal of Obesity</i> , 2021 , 45, 923-933	5.5	9
292	Etiopathogenesis of Obesity 2021 , 1-12		
291	PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviour after bariatric Surgery.. <i>BMJ Open</i> , 2021 , 11, e051638	3	0
290	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	11
289	The 1 α ,25(OH) ₂ D Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF- κ B and MAPK Signaling. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 1715-1724	3.4	0
288	Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. <i>Future Cardiology</i> , 2020 , 16, 77-88	1.3	5
287	Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 1793-1806	3.5	5
286	Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1094-1101	6.7	15

285	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1122-1134	6.7	13
284	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2020 , 141, 1227-1234	16.7	97
283	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1357-1368	6.7	13
282	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. <i>BMJ Open</i> , 2020 , 10, e034137	3	1
281	Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status. <i>European Journal of Endocrinology</i> , 2020 , 183, 211-220	6.5	3
280	Endocrine testing in obesity. <i>European Journal of Endocrinology</i> , 2020 , 182, C13-C15	6.5	5
279	1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. <i>Diabetes</i> , 2020 , 69, 1101-P	0.9	3
278	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020 , 11, 2757-2774	3.6	6
277	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020 , 36, 571-581	2.5	6
276	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , 2020 , 43, 468-475	14.6	33
275	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 27-35	18.1	109
274	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Peptides</i> , 2020 , 125, 170208	3.8	15
273	Weight loss is the major player in bariatric surgery benefits. <i>Nature Medicine</i> , 2020 , 26, 1678-1679	50.5	1
272	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020 , 142, 734-747	16.7	16
271	Randomised, controlled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). <i>BMJ Open</i> , 2020 , 10, e038856	3	2
270	Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2364-2374	6.7	11
269	Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity. <i>Global Health Action</i> , 2020 , 13, 1804700	3	5
268	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. <i>Obesity</i> , 2020 , 28, 1050-1061	8	77

267	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 140, 1569-1577	16.7	57
266	Semaglutide in weight management - Author@ reply. <i>Lancet, The</i> , 2019 , 394, 1226-1227	4.0	1
265	Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. <i>Diabetes Therapy</i> , 2019 , 10, 1995-2021	3.6	34
264	1 α 25(OH)D attenuates IL-6 and IL-1 β mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF- κ B signaling pathways. <i>Diabetology and Metabolic Syndrome</i> , 2019 , 11, 9	5.6	2
263	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 606-617	18.1	304
262	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 9-18	6.7	43
261	Incorporating patients@ perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000615	4.5	15
260	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019 , 139, 2516-2527	16.7	142
259	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2528-2536	16.7	283
258	Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. <i>Obesity Reviews</i> , 2019 , 20, 816-828	10.6	54
257	Should obesity be recognised as a disease?. <i>BMJ, The</i> , 2019 , 366, l4258	5.9	10
256	Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2019 , 155, 107791	7.4	5
255	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. <i>Diabetes Therapy</i> , 2019 , 10, 1595-1622	3.6	24
254	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. <i>Diabetes Therapy</i> , 2019 , 10, 2201-2217	3.6	5
253	1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. <i>Diabetes</i> , 2019 , 68, 1020-P	0.9	1
252	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. <i>Diabetes</i> , 2019 , 68, 244-OR	0.9	9
251	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2022-2031	16.7	345
250	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000700	4.5	18

249	Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. <i>Medicine and Science in Sports and Exercise</i> , 2019 , 51, 1169-1177	1.2	20
248	SGLT2 inhibitors and urinary tract infections. <i>Nature Reviews Endocrinology</i> , 2019 , 15, 687-688	15.2	10
247	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 347-357	59.2	2455
246	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , 2019 , 393, 31-39	40	1300
245	Obesity and Obstructive Sleep Apnea Syndrome. <i>Endocrinology</i> , 2019 , 243-271	0.1	
244	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". <i>Circulation</i> , 2019 , 139, 2000-2001	16.7	6
243	Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. <i>Diabetologia</i> , 2018 , 61, 1282-1294	10.3	54
242	Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. <i>Clinical Obesity</i> , 2018 , 8, 211-225	3.6	6
241	Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome. <i>Appetite</i> , 2018 , 125, 270-277	4.5	2
240	Newer GLP-1 receptor agonists and obesity-diabetes. <i>Peptides</i> , 2018 , 100, 61-67	3.8	29
239	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018 , 200, 83-89	4.9	89
238	DECLARE-TIMI 58: Participants Baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1107-1108	4.9	89
237	Obesity and Obstructive Sleep Apnea Syndrome. <i>Endocrinology</i> , 2018 , 1-30	0.1	
236	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2628-2639	15.1	263
235	Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1983-1987	6.7	55
234	Medication use for the treatment of diabetes in obese individuals. <i>Diabetologia</i> , 2018 , 61, 265-272	10.3	25
233	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. <i>Diabetes Therapy</i> , 2018 , 9, 1757-1773	3.6	39
232	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018 , 16, 116	11.4	28

231	Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. <i>Diabetes Therapy</i> , 2018 , 9, 1791-1810	3.6	9
230	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 637-649	4.0	24.2
229	Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes: The Energize Study. <i>Diabetes</i> , 2018 , 67, 1163-P	0.9	3
228	HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in U.K. Primary Care Patients with Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1186-P	0.9	
227	Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1175-P	0.9	
226	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. <i>Diabetes</i> , 2018 , 67, 1191-P	0.9	
225	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018 , 146, 240-250	7.4	14
224	Time for a new obesity narrative. <i>Lancet, The</i> , 2018 , 392, 1384-1386	4.0	3.0
223	Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. <i>Obesity Reviews</i> , 2018 , 19, 1569-1584	10.6	21
222	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. <i>Trials</i> , 2018 , 19, 427	2.8	6
221	SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2497-2506	15.1	68
220	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2210-2219	6.7	44
219	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6-10. <i>Diabetes Care</i> , 2018 , 41, e106-e108	14.6	8
218	Vitamin D receptor ligands attenuate the inflammatory profile of IL-1 β -stimulated human white preadipocytes via modulating the NF- κ B and unfolded protein response pathways. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 503, 1049-1056	3.4	12
217	Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol. <i>BMJ Open</i> , 2017 , 7, e013539	3	12
216	What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. <i>International Journal of Obesity</i> , 2017 , 41, 853-865	5.5	68
215	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017 , 389, 1399-1409	4.0	32.4
214	Consensus recommendations on exploring effective solutions for the rising cost of diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017 , 11, 141-147	8.9	6

213	Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017 , 312, E224-E233	6	33
212	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2017 , 71, e12948	2.9	14
211	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). <i>Circulation</i> , 2017 , 136, 249-259	16.7	519
210	Screening methods for obstructive sleep apnoea in severely obese pregnant women. <i>Clinical Obesity</i> , 2017 , 7, 239-244	3.6	3
209	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 597-609	18.1	177
208	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1529-1536	6.7	27
207	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017 , 66, 241-255	25.5	292
206	SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials. <i>Trials</i> , 2017 , 18, 597	2.8	10
205	Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement. <i>Clinical Obesity</i> , 2017 , 7, 368-376	3.6	9
204	Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. <i>Experimental Physiology</i> , 2017 , 102, 1424-1434	2.4	12
203	Combination therapy for obesity. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1503-1508	4.6	20
202	Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. <i>Primary Care Diabetes</i> , 2017 , 11, 437-444	2.4	13
201	Etiopathogenesis of Obesity 2016 , 13-20		
200	Weighing up dietary patterns - Authors Reply. <i>Lancet, The</i> , 2016 , 388, 759-60	40	2
199	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016 , 68, 606-13	8.5	18
198	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S154-64	14.6	28
197	Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. <i>Obesity</i> , 2016 , 24, 2278-2288	8	60
196	SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 379-81	18.1	6

195	Fit for Birth - the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study. <i>Clinical Obesity</i> , 2016 , 6, 79-88	3.6	9
194	Management of obesity. <i>Lancet, The</i> , 2016 , 387, 1947-56	4.0	461
193	Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes 2016 , 1,		3
192	Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. <i>Journal of Obesity</i> , 2016 , 2016, 7127898	3.7	10
191	Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 125-34	6.7	50
190	Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. <i>Diabetes Therapy</i> , 2016 , 7, 695-711	3.6	18
189	Research update for articles published in EJCI in 2014. <i>European Journal of Clinical Investigation</i> , 2016 , 46, 880-94	4.6	
188	GLP-1 as a target for therapeutic intervention. <i>Current Opinion in Pharmacology</i> , 2016 , 31, 44-49	5.1	20
187	Exposure-response analyses of liraglutide 3.0 mg for weight management. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 491-9	6.7	40
186	Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. <i>Diabetic Medicine</i> , 2016 , 33, 864-76 ^{3.5}		7
185	Impact of bariatric surgery on physical functioning in obese adults. <i>Obesity Reviews</i> , 2015 , 16, 248-58	10.6	36
184	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. <i>New England Journal of Medicine</i> , 2015 , 373, 11-22	59.2	950
183	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 438-44	3.2	38
182	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. <i>Diabetologia</i> , 2015 , 58, 1183-7	10.3	89
181	Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea. <i>Sleep and Breathing</i> , 2015 , 19, 1155-65	3.1	11
180	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015 , 385, 2067-76	4.0	551
179	Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study. <i>International Journal of Obesity</i> , 2015 , 39, 1376-82	5.5	2
178	Obesity and cardiovascular risk in type 2 diabetes 2015 , 119-128		

177	Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. <i>International Journal of Clinical Practice</i> , 2015 , 69, 186-98	2.9	13
176	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
175	Serum urate and obstructive sleep apnoea in severe obesity. <i>Chronic Respiratory Disease</i> , 2015 , 12, 238-46		9
174	Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. <i>Sleep Science</i> , 2015 , 8, 58-67	1.8	2
173	Pathophysiology and aetiology of obesity. <i>Medicine</i> , 2015 , 43, 73-76	0.6	8
172	SGLT2 inhibition and ketoacidosis [should we be concerned?]. <i>British Journal of Diabetes and Vascular Disease</i> , 2015 , 15, 155		9
171	The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 1228-37	12.7	115
170	Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 124-36	6.7	198
169	The importance of weight management in type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2014 , 68, 682-91	2.9	133
168	Liraglutide in the treatment of obesity. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1215-24	5.4	14
167	The clinical management of diabetes mellitus 2014 , 305-332		4
166	A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1535-44	4.1	8
165	Effect of a cooked meat meal on serum creatinine and estimated glomerular filtration rate in diabetes-related kidney disease. <i>Diabetes Care</i> , 2014 , 37, 483-7	14.6	37
164	Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. <i>Clinical Science</i> , 2014 , 127, 655-63	6.5	4
163	Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. <i>Chronic Respiratory Disease</i> , 2014 , 11, 257-75	3	32
162	Characteristics and perspectives of night-eating behaviour in a severely obese population. <i>Clinical Obesity</i> , 2014 , 4, 30-8	3.6	10
161	Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. <i>BMJ, The</i> , 2014 , 349, g6608	5.9	115
160	Urinary proteomics in obstructive sleep apnoea and obesity. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 1104-15	4.6	14

159	Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity. <i>Journal of Sleep Research</i> , 2014 , 23, 700-708	5.8	22
158	Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 159-69	6.7	321
157	Obstructive sleep apnoea in diabetes - assessment and awareness. <i>British Journal of Diabetes and Vascular Disease</i> , 2014 , 14, 105		4
156	Glucose metabolism and the pathophysiology of diabetes mellitus 2014 , 273-304		2
155	Screening for obstructive sleep apnoea in obesity and diabetes--potential for future approaches. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 640-55	4.6	16
154	Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 375-91	3.7	6
153	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2013 , 369, 1327-35	59.2	1858
152	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 268-73	3.2	68
151	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. <i>International Journal of Clinical Practice</i> , 2013 , 67, 1267-82	2.9	245
150	Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population. <i>Sleep Medicine</i> , 2013 , 14, 1151-6	4.6	7
149	Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. <i>Regulatory Peptides</i> , 2013 , 183, 54-61		23
148	Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 403-9	6.7	98
147	Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. <i>Endocrine</i> , 2013 , 43, 696-704	4	9
146	Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. <i>European Journal of Endocrinology</i> , 2013 , 168, 501-7	6.5	14
145	How to approach endocrine assessment in severe obesity?. <i>Clinical Endocrinology</i> , 2013 , 79, 163-7	3.4	12
144	Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 750-9	6.7	59
143	232 DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENOSIS WITH A NORMAL EJECTION FRACTION. <i>Heart</i> , 2013 , 99, A125.1-A125	5.1	
142	1,25-dihydroxyvitamin D3 protects against macrophage-induced activation of NF κ B and MAPK signalling and chemokine release in human adipocytes. <i>PLoS ONE</i> , 2013 , 8, e61707	3.7	65

141	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 973-82	6.7	50
140	Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 990-9	6.7	154
139	Reply to Camargo et al. <i>Diabetic Medicine</i> , 2012 , 29, 1086-7; author reply 1087-8	3.5	
138	Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2012 , 29, e205-10	3.5	36
137	Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. <i>Annals of Internal Medicine</i> , 2012 , 156, 405-15	8	340
136	A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2012 , 77, 635-7	3.4	20
135	Vitamin D signalling in adipose tissue. <i>British Journal of Nutrition</i> , 2012 , 108, 1915-23	3.6	210
134	Anti-obesity drugs: past, present and future. <i>DMM Disease Models and Mechanisms</i> , 2012 , 5, 621-6	4.1	306
133	Are the causes of obesity primarily environmental? Yes. <i>BMJ, The</i> , 2012 , 345, e5843	5.9	17
132	The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. <i>Thorax</i> , 2012 , 67, 920-4	7.3	29
131	Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1020-31	5.6	548
130	Night eating syndrome: implications for severe obesity. <i>Nutrition and Diabetes</i> , 2012 , 2, e44	4.7	45
129	Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. <i>Chest</i> , 2012 , 141, 616-624	5.3	38
128	Glucagon-like peptide-1 analogues for type 2 diabetes. <i>BMJ, The</i> , 2011 , 342, d410	5.9	15
127	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type 2 diabetic chronic kidney disease. <i>Diabetic Medicine</i> , 2011 , 28, 1279	3.5	6
126	Human RBP4 adipose tissue expression is gender specific and influenced by leptin. <i>Clinical Endocrinology</i> , 2011 , 74, 197-205	3.4	29
125	Pathophysiology and aetiology of obesity. <i>Medicine</i> , 2011 , 39, 6-10	0.6	6
124	The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. <i>Diabetologia</i> , 2011 , 54, 1304-7	10.3	36

123	Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. <i>European Journal of Endocrinology</i> , 2011 , 165, 45-55	6.5	11
122	The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. <i>Clinical Endocrinology</i> , 2010 , 72, 334-41	3.4	84
121	Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. <i>Clinical Endocrinology</i> , 2010 , 73, 678-85	3.4	21
120	In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 360-3	6.7	5
119	Nurse-led clinics for strict hypertension control are effective long term: a 7 year follow-up study. <i>Diabetic Medicine</i> , 2010 , 27, 933-7	3.5	7
118	Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 34-42	5.6	195
117	The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. <i>Journal of Psychopharmacology</i> , 2010 , 24, 99-109	4.6	30
116	SPARC: a key player in the pathologies associated with obesity and diabetes. <i>Nature Reviews Endocrinology</i> , 2010 , 6, 225-35	15.2	98
115	The endocrinologist and respiratory failure 2010 , 391-398		
114	Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. <i>Age</i> , 2010 , 32, 209-22		29
113	From history to reality: sodium glucose co-transporter 2 inhibitors – a novel therapy for type 2 diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2010 , 27, 311-316		9
112	Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. <i>Diabetes</i> , 2009 , 58, 1780-8	0.9	86
111	A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. <i>Diabetes Care</i> , 2009 , 32, 1656-62	14.6	312
110	Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. <i>Endocrinology</i> , 2009 , 150, 1688-96	4.8	137
109	Modern management of obesity. <i>Clinical Medicine</i> , 2009 , 9, 617-21; quiz 622-3	1.9	3
108	Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. <i>Clinical Endocrinology</i> , 2009 , 71, 195-201	3.4	43
107	Ghrelin restores lean-type hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. <i>International Journal of Obesity</i> , 2009 , 33, 317-25	5.5	27
106	Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 733-41	6.7	22

105	Adipokines: emerging therapeutic targets. <i>Current Opinion in Investigational Drugs</i> , 2009 , 10, 1061-8		6
104	Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. <i>International Journal of Obesity</i> , 2008 , 32, 129-35	5.5	55
103	Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 251-63	6.7	7
102	Growth hormone and changes in energy balance in growth hormone deficient adults. <i>European Journal of Clinical Investigation</i> , 2008 , 38, 622-7	4.6	6
101	Anti-obesity Drugs: From Animal Models to Clinical Efficacy 2008 , 271-315		4
100	Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. <i>Diabetes Research and Clinical Practice</i> , 2008 , 81, 2-12	7.4	224
99	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. <i>British Journal of Diabetes and Vascular Disease</i> , 2008 , 8, 170-176		1
98	Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008 , 25, 54-58		0
97	Regulation of energy balance [towards rational drug design in obesity 2008 , 21-46		
96	Intestinal lipase inhibitors 2008 , 47-57		
95	Sibutramine 2008 , 59-68		
94	The endocannabinoid system as a target for obesity treatment 2008 , 69-80		
93	Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenological study. <i>Nutrition and Metabolism</i> , 2007 , 4, 15	4.6	9
92	A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1696-704	15.1	170
91	Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 299-303	7.5	28
90	An elderly type 1 diabetic patient with life event-related brittle diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2007 , 24, 130-131		
89	Treatment strategies for obesity. <i>Obesity Reviews</i> , 2007 , 8 Suppl 1, 137-44	10.6	21
88	Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. <i>Diabetes, Obesity and Metabolism</i> , 2007 , 9, 114-20	6.7	17

87	The importance of free fatty acids in the development of Type 2 diabetes. <i>Diabetic Medicine</i> , 2007 , 24, 934-45	3.5	133
86	Clinical Investigations of Antiobesity Drugs 2007 , 337-III		3
85	Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2007 , 4, 194-203	3.3	33
84	Cardiovascular and metabolic effects of CPAP in obese males with OSA. <i>European Respiratory Journal</i> , 2007 , 29, 720-7	13.6	237
83	Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. <i>Postgraduate Medical Journal</i> , 2007 , 83, 277-80	2	18
82	Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. <i>Journal of Psychopharmacology</i> , 2007 , 21, 405-13	4.6	86
81	Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. <i>Bone</i> , 2007 , 41, 406-13	4.7	26
80	Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. <i>Diabetologia</i> , 2006 , 49, 2219-21	10.3	15
79	Pathophysiology and aetiology of obesity. <i>Medicine</i> , 2006 , 34, 501-505	0.6	7
78	Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. <i>Postgraduate Medical Journal</i> , 2006 , 82, 280-4	2	185
77	Obesity and risk of myocardial infarction: the INTERHEART study. <i>Lancet, The</i> , 2006 , 367, 1053	40	5
76	Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. <i>Diabetic Medicine</i> , 2006 , 23, 780-7	3.5	26
75	Applied physiology: The control of weight. <i>Current Paediatrics</i> , 2006 , 16, 439-446		
74	Gut peptides and the regulation of appetite. <i>Obesity Reviews</i> , 2006 , 7, 163-82	10.6	162
73	Thiazolidinediones, insulin resistance and obesity: Finding a balance. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1272-80	2.9	52
72	Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2005 , 7, 755-61	6.7	97
71	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?. <i>Diabetic Medicine</i> , 2005 , 22, 666-7; author reply 667	3.5	2
70	Improved glycaemic control—an unintended benefit of a nurse-led cardiovascular risk reduction clinic. <i>Diabetic Medicine</i> , 2005 , 22, 1272-4	3.5	14

69	The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. <i>British Journal of Pharmacology</i> , 2005 , 144, 308-16	8.6	62
68	Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. <i>Diabetologia</i> , 2005 , 48, 2641-9	10.3	29
67	A parametric analysis of olanzapine-induced weight gain in female rats. <i>Psychopharmacology</i> , 2005 , 181, 80-9	4.7	103
66	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. <i>Heart</i> , 2005 , 91, 32-7	5.1	51
65	Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5025-30	5.6	22
64	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. <i>Diabetic Medicine</i> , 2004 , 21, 415-22	3.5	65
63	The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. <i>Clinical Endocrinology</i> , 2004 , 60, 137-41	3.4	29
62	Body weight and prolactinoma: a retrospective study. <i>International Journal of Obesity</i> , 2004 , 28, 183	5.5	6
61	A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. <i>International Journal of Obesity</i> , 2004 , 28, 1399-410	5.5	166
60	Response: Postprandial Adiponectin Revisited. <i>Obesity</i> , 2004 , 12, 1032-1034		4
59	Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. <i>Brain Research</i> , 2004 , 1016, 222-8	3.7	19
58	Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal. <i>Diabetes/Metabolism Research and Reviews</i> , 2004 , 20, 405-10	7.5	22
57	Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. <i>European Heart Journal</i> , 2004 , 25, 735-41	9.5	539
56	Clinical evaluation of anti-obesity drugs. <i>Current Drug Targets</i> , 2004 , 5, 325-32	3	11
55	Intensified treatment of type 2 diabetes--positive effects on blood pressure, but not glycaemic control. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003 , 96, 833-6	2.7	20
54	Obesity and type-2 diabetes in the elderly. <i>Gerontology</i> , 2003 , 49, 137-45	5.5	8
53	Pathophysiology and Aetiology of Obesity. <i>Medicine</i> , 2003 , 31, 1-4	0.6	1
52	Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gains of rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2003 , 30, 513-4; author reply 514-5	3	

51	Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. <i>International Journal of Experimental Pathology</i> , 2003 , 84, 83-9	2.8	13
50	Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. <i>Clinical Endocrinology</i> , 2003 , 59, 75-81	3.4	27
49	Plasma adiponectin increases postprandially in obese, but not in lean, subjects. <i>Obesity</i> , 2003 , 11, 839-44		54
48	Neuropeptides and appetite control. <i>Diabetic Medicine</i> , 2002 , 19, 619-27	3.5	125
47	Hypothalamic obesity in humans: what do we know and what can be done?. <i>Obesity Reviews</i> , 2002 , 3, 27-34	10.6	56
46	Food fails to suppress ghrelin levels in obese humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2984	5.6	340
45	Ghrelin: sweet regulation?. <i>Clinical Science</i> , 2002 , 103, 329-30	6.5	1
44	Obesity: under-diagnosed and under-treated in hospital outpatient departments. <i>International Journal of Obesity</i> , 2002 , 26, 581-4	5.5	14
43	Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. <i>International Journal of Clinical Practice</i> , 2002 , 56, 494-9	2.9	62
42	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. <i>Clinical Science</i> , 2001 , 100, 635-41	6.5	40
41	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. <i>Clinical Science</i> , 2001 , 101, 499-506	6.5	38
40	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. <i>Clinical Science</i> , 2001 , 100, 635	6.5	18
39	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. <i>Clinical Science</i> , 2001 , 101, 499	6.5	19
38	An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. <i>Clinical Endocrinology</i> , 2001 , 54, 463-8	3.4	95
37	The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2001 , 54, 819-26	3.4	10
36	Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. <i>Diabetes, Obesity and Metabolism</i> , 2001 , 3, 171-80	6.7	19
35	Sleep disordered breathing--a new component of syndrome x?. <i>Obesity Reviews</i> , 2001 , 2, 267-74	10.6	38
34	Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. <i>British Journal of Pharmacology</i> , 2001 , 132, 1898-904	8.6	27

33	Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. <i>European Journal of Pharmacology</i> , 2001 , 416, 133-9	5.3	8
32	Leptin and the control of obesity. <i>Current Opinion in Pharmacology</i> , 2001 , 1, 656-61	5.1	26
31	Evolution of Early Changes in Heart Rate Variability following Acute Myocardial Infarction. <i>Clinical Science</i> , 2000 , 99, 15P-16P		
30	Obesity and Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2000 , 17, 400-2	3.5	1
29	Management of hypertension 2000 , 320, 576-576		4
28	Abnormal heart rate variability in adults with growth hormone deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 628-33	5.6	20
27	Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. <i>Archives of Internal Medicine</i> , 2000 , 160, 1321-6		250
26	Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone. <i>Molecular Brain Research</i> , 2000 , 77, 131-7		63
25	The future of obesity treatment. <i>Exs</i> , 2000 , 89, 181-91		3
24	Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. <i>Postgraduate Medical Journal</i> , 1999 , 75, 467-70	2	28
23	Hypothalamic orexin expression: modulation by blood glucose and feeding. <i>Diabetes</i> , 1999 , 48, 2132-7	0.9	266
22	Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. <i>British Journal of Pharmacology</i> , 1999 , 128, 1570-6	8.6	117
21	Obesity and diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 1999 , 13, 221-87		41
20	Sympathovagal Balance in Growth Hormone Deficient Patients. <i>Clinical Science</i> , 1999 , 97, 6P-6P		
19	Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 1021-6	9.4	51
18	Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. <i>Journal of Endocrinology</i> , 1997 , 152, 365-9	4.7	39
17	Endocrine effects of gastrointestinal tumours. <i>Endocrine-Related Cancer</i> , 1997 , 4, 179-189	5.7	1
16	Neurobiology. <i>British Medical Bulletin</i> , 1997 , 53, 286-306	5.4	20

15	Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1997 , 9, 68-73	4.6	
14	Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 1997 , 27, 533-6	4.6	90
13	Science, medicine, and the future. Obesity treatment. <i>BMJ: British Medical Journal</i> , 1997 , 315, 997-1000		48
12	Metabolic actions of neuropeptide Y and their relevance to obesity. <i>Biochemical Society Transactions</i> , 1996 , 24, 576-81	5.1	5
11	Reduced NPY induced feeding in diabetic but not steroid-treated rats: lack of evidence for changes in receptor number or affinity. <i>Journal of Neuroendocrinology</i> , 1996 , 8, 283-90	3.8	10
10	A role for glucagon-like peptide-1 in the central regulation of feeding. <i>Nature</i> , 1996 , 379, 69-72	50.4	1520
9	E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. <i>Cancer Research</i> , 1996 , 56, 5285-92	10.1	49
8	Acute effects of central neuropeptide Y injection on glucose metabolism in fasted rats. <i>Clinical Science</i> , 1995 , 89, 543-8	6.5	7
7	Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. <i>Diabetologia</i> , 1994 , 37, 166-9	10.3	41
6	Effect of food deprivation and streptozotocin-induced diabetes on hypothalamic neuropeptide Y release as measured by a radioimmunoassay-linked microdialysis procedure. <i>Brain Research</i> , 1994 , 656, 135-40	3.7	32
5	Dietary advice based on the glycaemic index improves dietary profile and metabolic control in type 2 diabetic patients. <i>Diabetic Medicine</i> , 1994 , 11, 397-401	3.5	135
4	Increases in neuropeptide Y content and gene expression in the hypothalamus of rats treated with dexamethasone are prevented by insulin. <i>Neuroendocrinology</i> , 1993 , 57, 581-7	5.6	60
3	Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. <i>Journal of Endocrinology</i> , 1992 , 132, 299-304	4.7	73
2	Pharmacological Approaches for Treating Obesity421-446		2
1	Is Obesity Realistically Treatable in Type 2 Diabetes?73-87		